Chromadex Corp (NASDAQ:CDXC) Expected to Post Earnings of -$0.12 Per Share

Equities analysts predict that Chromadex Corp (NASDAQ:CDXC) will post earnings per share of ($0.12) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Chromadex’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Chromadex reported earnings per share of ($0.15) during the same quarter last year, which would indicate a positive year over year growth rate of 20%. The company is expected to announce its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Chromadex will report full-year earnings of ($0.42) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.33). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.14) to $0.19. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Chromadex.

Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.04). The business had revenue of $10.05 million during the quarter, compared to analysts’ expectations of $9.80 million. Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%.

A number of equities research analysts have issued reports on CDXC shares. BidaskClub raised Chromadex from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Zacks Investment Research downgraded Chromadex from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Chromadex in a research report on Thursday, April 25th. Finally, ValuEngine raised Chromadex from a “hold” rating to a “buy” rating in a research report on Monday, March 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Hedge funds have recently bought and sold shares of the business. Northern Trust Corp grew its position in Chromadex by 1.2% during the fourth quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock valued at $1,412,000 after acquiring an additional 5,009 shares during the period. Rhumbline Advisers boosted its position in shares of Chromadex by 53.3% in the fourth quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock worth $166,000 after buying an additional 16,863 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Chromadex by 23.4% in the fourth quarter. Bank of New York Mellon Corp now owns 128,810 shares of the company’s stock worth $442,000 after buying an additional 24,408 shares during the period. Granite Investment Partners LLC boosted its position in shares of Chromadex by 87.7% in the first quarter. Granite Investment Partners LLC now owns 167,689 shares of the company’s stock worth $702,000 after buying an additional 78,373 shares during the period. Finally, Sargent Investment Group LLC purchased a new stake in shares of Chromadex in the fourth quarter worth about $355,000. 18.11% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CDXC opened at $3.89 on Tuesday. The firm has a market capitalization of $227.08 million, a PE ratio of -6.38 and a beta of 1.16. The company has a quick ratio of 1.68, a current ratio of 2.24 and a debt-to-equity ratio of 0.07. Chromadex has a 52 week low of $2.79 and a 52 week high of $5.00.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Featured Story: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.